Solo Therapeutics, a Boston, MA-based biotechnology company advancing therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, raised $41M in Series A funding.
Backers included participation from five new investors Eli Lilly and Company, Biovision Ventures, Pappas Capital, Hengdian Group Capital (HgC), and The Leukemia & Lymphoma Society Therapy Acceleration Program, as well as continued support from existing Solu investors Longwood Fund, DCVC Bio, Santé Ventures, Astellas Venture Management, and Alexandria Venture Investments.
The company intends to use the funds to complete dose escalation and expand its lead CCR2-CyTAC program, STX-0712, for the treatment of CMML. Additionally, the funding will support the generation of new development candidates, including a novel, first-in-class mast cell depletor for immunological diseases, initiation of new discovery programs targeting pathogenic cells, further pipeline expansion, and exploration of new applications for the CyTAC and TicTAC platforms.
Led by CEO and President Philip J. Vickers, Solu Therapeutics is a biotechnology company cofounded by Longwood Fund and committed to developing an innovative class of therapeutic agents that pair small molecules with monoclonal antibodies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas. By leveraging its proprietary CyTAC (Cytotoxicity Targeting Chimera) and TicTAC (Therapeutic Index Control Targeting Chimera) platforms, Solu is advancing therapies that combine the target-binding capability of small molecules with the therapeutic power of biologics. Its lead product candidate, STX-0712, is currently in Phase 1 clinical development for the treatment of advanced hematologic malignancies including CMML.
FinSMEs
09/04/2025